NYSE$AVD

American Vanguard Corporation · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

American Vanguard reported an increase in net sales and improved operating leverage in Q1 2024.

American Vanguard reported Q1 2024 results with net sales of $135 million, a 35% increase in adjusted EBITDA, and an 87% increase in operating income compared to Q1 2023. Growth was experienced across all three business segments. The company is adjusting its annual targets in light of concerns raised by USEPA and has voluntarily suspended sales of its herbicide Dacthal pending potential approval of a label.

  • Net sales increased to $135 million from $125 million year-over-year.
  • Adjusted EBITDA rose to $15.5 million from $11.5 million year-over-year.
  • Operating income increased to $6.1 million from $3.3 million year-over-year.
  • Net income decreased to $1.6 million from $1.9 million year-over-year.

Headline financials

Total Revenue

$135M

Previous: $125M+8.2%
EPS

$0.06

Previous: $0.07-14.3%
Gross Margin

31.0%

No prior period
Adjusted EBITDA

$15.5M

No prior period
Capital Expenditures

-$3.57M

Previous: -$2.59M-37.6%
Free Cash Flow

-$2.01M

Previous: -$672K-199.6%
Net Income

$1.55M

Previous: $1.92M-19.1%
Operating Income

$6.09M

Previous: $3.27M+86.6%
Gross Profit

$42.4M

Previous: $38.5M+10.1%
Cash & Equivalents

$13.7M

Previous: $19.6M-29.9%
Total Assets

$782M

Previous: $771M+1.4%
R&D Expense

$5.71M

No prior period
Stock-Based Comp

$2.01M

Previous: $1.47M+36.0%

Revenue & EPS history

American Vanguard · Revenue · Quarterly

$135M

Q1 2024+8.2%vs Q1 2023
Beat estimate in 5 of 13 quarters(38%)
ActualEstimate

Revenue by segment

American Vanguard · $150M total across 3 segments · Q3 2023

  • U.S. Crop
    $67.7M-2.0%
  • International
    $62.5M-2.4%
  • U.S. Non-Crop
    $19.3M+1.7%

Forward guidance

The company is adjusting its annual targets to achieve an increase in net sales of between 6% and 9% year over year and are setting adjusted EBITDA target to $60 - $70 million.

Tailwinds

  • Targeting a net sales increase of 6% to 9% year-over-year.
  • Adjusted EBITDA target set at $60 to $70 million.

Headwinds

  • Voluntarily suspended sales of herbicide Dacthal.
  • Suspension is pending potential approval of a label.
  • Suspension due to concerns raised by USEPA.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-1.0%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.6%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+18.9%

Q4 2015

Best reaction

-34.9%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.4%-1.0%-9.8%
Q4 2025-9.6%-30.9%-24.6%
Q3 2025-0.8%-0.4%-14.9%
Q1 2025-9.2%-8.5%-19.2%
Q4 2024-5.7%+6.2%-20.0%
Q3 2024+2.1%+5.0%-5.7%
Q2 2024-34.9%-28.5%-20.5%
Q1 2024-26.6%-30.6%-30.4%
Q4 2023+15.3%+9.4%+4.5%
Q3 2023+1.1%-12.3%+5.1%
Q2 2023-16.6%-13.1%-24.7%
Q1 2023-12.9%-9.9%-3.1%
Q4 2022+4.9%+5.5%+7.8%
Q3 2022-4.4%-6.6%-4.8%
Q2 2022-18.2%-15.5%-19.8%
Q1 2022+5.6%-4.5%+17.9%
Q4 2021+2.6%+6.5%+24.0%
Q3 2021+4.3%+3.0%-9.2%
Q2 2021-0.7%-6.6%-3.5%
Q1 2021-3.3%-5.8%-14.6%
Q4 2020+2.1%-2.0%-8.6%
Q3 2020+9.2%+8.3%+21.8%
Q2 2020+4.6%+3.0%+1.0%
Q1 2020-1.9%-9.6%-3.1%
Q4 2019-4.6%-9.3%+2.3%
Q3 2019+5.0%+6.4%+8.4%
Q2 2019+5.4%+3.0%+13.8%
Q1 2019-0.3%-8.3%-19.6%
Q4 2018+6.2%-1.1%-2.1%
Q3 2018-5.6%-1.9%-7.5%
Q2 2018-4.2%-9.3%-4.0%
Q1 2018+11.7%+0.9%+10.5%
Q4 2017+16.0%+15.5%+9.8%
Q3 2017-6.1%-10.1%-10.8%
Q2 2017+9.7%+13.1%+10.0%
Q1 2017+10.9%+9.1%+9.4%
Q4 2016-4.0%-6.2%+4.7%
Q3 2016+0.3%+3.3%+14.3%
Q2 2016+17.6%+16.2%+12.2%
Q1 2016-21.8%
Q4 2015+18.9%
Q3 2015+14.0%
Q2 2015+0.8%
Q1 2015+14.6%
Q4 2014-1.7%
Q3 2014+6.4%
Q2 2014+2.6%
Q1 2014-13.1%
Q4 2013-4.3%
Q3 2013+8.9%
Q2 2013+3.3%
Q1 2013+7.7%
Q4 2009+0.2%
Q4 2012-11.0%
Q3 2012+1.7%
Q2 2012+12.5%
Q1 2012+4.1%
Q4 2011+2.0%
Q3 2010-6.8%
Q3 2011-6.8%
Q2 2010-15.6%
Q1 2011-15.6%
Q2 2011-15.6%
Q4 2010-15.6%
Q1 2010+4.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro